Peginterferon α-2b

also known as PEG-IFN-α-2b · Peg-Intron · pegylated interferon alfa-2b · pegylated interferon alpha-2b

Developed for: chronic hepatitis B virus infection · essential thrombocythemia · acquired polycythemia vera · anogenital human papillomavirus infection · cancer · chronic hepatitis C virus infection · chronic myeloid leukemia · hand, foot and mouth disease
+2 more
· respiratory syncytial virus bronchiolitis · respiratory syncytial virus infectious disease
Investigated by: Xiamen Amoytop Biotech Co., Ltd. · Children's Hospital of Soochow University · French National Agency for Research on AIDS and Viral Hepatitis · Merck Sharp & Dohme LLC · Peking University First Hospital · Qing XIe
+8 more
· The First Affiliated Hospital of Xiamen University · Third Affiliated Hospital, Sun Yat-Sen University · University of Jena · West China Second University Hospital · Xiamen Hospital of Traditional Chinese Medicine · Zhangyu Bu · Zhengzhou Children's Hospital, China · Zhenya Hong

Trials 13 · a red edge is where a trial was stopped

today NCT07438093 · not/applicable NCT06920329 · not/applicable NCT06827249 · not/applicable NCT06734637 · not/applicable NCT06552429 · Ph 2 NCT07008755 · not/applicable NCT06881056 · not/applicable NCT06430190 · not/applicable NCT06323681 · not/applicable NCT06707922 · not/applicable NCT04035837 · Ph 4 NCT01657604 · Ph 3 NCT01463956 · Ph 2

201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 22 trials
Phase 2	NCT06552429	Aug 2024 → Oct 2025 overdue	essential thrombocythemia	Xiamen Amoytop Biotech Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT01463956	Jan 2012 → Jun 2014	chronic hepatitis C virus infection, cirrhosis of liver	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT01657604	Aug 2012 → May 2022	chronic myeloid leukemia	University of Jena	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT04035837	May 2018 → Dec 2025 overdue	chronic hepatitis B virus infection	Third Affiliated Hospital, Sun Yat-Sen University	Active not recruiting	No outcome recorded
Phase not applicable9 trials
—	NCT07438093	Apr 2026 → Apr 2027 expected	cancer	The First Affiliated Hospital of Xiamen University	Not yet recruiting	No outcome recorded
—	NCT06920329	Apr 2025 → Dec 2027 expected	chronic hepatitis B virus infection	Xiamen Hospital of Traditional Chinese Medicine	Not yet recruiting	No outcome recorded
—	NCT06827249	Mar 2025 → Jun 2026 overdue	respiratory syncytial virus bronchiolitis	Children's Hospital of Soochow University	Recruiting	No outcome recorded
—	NCT06734637	Nov 2024 → Nov 2026 expected	acquired polycythemia vera, essential thrombocythemia	Zhenya Hong	Recruiting	No outcome recorded
—	NCT07008755	Jul 2024 → Oct 2027 expected	hand, foot and mouth disease	Zhengzhou Children's Hospital, China	Recruiting	No outcome recorded
—	NCT06881056	Jul 2024 → Dec 2025 overdue	respiratory syncytial virus infectious disease	West China Second University Hospital	Recruiting	No outcome recorded
—	NCT06430190	Jul 2024 → Jan 2025	anogenital human papillomavirus infection	Zhangyu Bu	Unknown	No outcome recorded
—	NCT06323681	Feb 2024 → Feb 2027 expected	chronic hepatitis B virus infection	Qing XIe	Recruiting	No outcome recorded
—	NCT06707922	Mar 2022 → May 2029 expected	chronic hepatitis B virus infection	Xiamen Amoytop Biotech Co., Ltd.	Enrolling by invitation	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01949168 Comparator	Sep 2013 → Sep 2015	chronic hepatitis C virus infection	St Vincent's Hospital Melbourne	Unknown	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 16 sources stand behind the page.

Field	Value	Cited text
Known as	Peginterferon α2b	“Peginterferon α-2b Enhances Hepatitis B Surface Antigen Loss in Nucleos(t)ide Analogue-Suppressed Low Hepatitis B Surface Antigen Chronic Hepatitis B Patients: Everest Study in China.” PMID 41638418 ↗ Feb 2026 14 “Peginterferon α2b Injection in the Treatment of Pediatric RSV Bronchiolitis” NCT06827249 ↗ NCT01657604 ↗ NCT06430190 ↗ NCT07008755 ↗ NCT06707922 ↗ NCT06827249 ↗ NCT06552429 ↗ NCT06881056 ↗ NCT06920329 ↗ NCT06323681 ↗ NCT01949168 ↗ NCT01463956 ↗ NCT07438093 ↗ NCT06734637 ↗
Known as	PEG-IFN-α-2b	“Patients with NA-suppressed CHB who were hepatitis B e antigen (HBeAg)-negative, had HBsAg ≤1500 IU/mL, and undetectable HBV DNA, were administered PegIFNα-2b for 48 weeks,...” PMID 41638418 ↗ Feb 2026 2 “All patients received PEG-IFN-α-2b-based therapy, achieved HBV DNA negativity and HBsAg clearance, and were followed-up for at least 48 weeks after discontinuation of medications.” PMID 40390028 ↗ May 2025 “pegylated interferon alpha-2b (Peg-IFNα2b) combined with PD-1 monoclonal antibody.” NCT07438093 ↗
Known as	Peg-Intron	“Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection” NCT01949168 ↗
Known as	pegylated interferon alfa-2b	“Pegylated interferon alfa-2b (Peg-IFN α-2b), a first-line treatment for hepatitis B virus (HBV) infection, can significantly achieve HBsAg clearance in clinic.” PMID 36944116 ↗ Mar 2023
Known as	pegylated interferon alpha-2b	“pegylated interferon alpha-2b (Peg-IFNα2b) combined with PD-1 monoclonal antibody.” NCT07438093 ↗
Modality	Protein / enzyme biologic	“pegylated interferon alpha-2b (Peg-IFNα2b)” NCT07438093 ↗
Route	Subcutaneous	“Peg-Interferon α-2b by subcutaneous injection” NCT01463956 ↗